Through drug screening, we identified dyclonine, an oral anesthetic and ALDH enzyme inhibitor, as a compound that re-sensitizes sulfasalazine-resistant cancer cells to SLC7A11 inhibitors.59 Dyclonine enhances SLC7A11-targeted therapy and induces necrotic cell death in squamous cell carcinoma. The gene discussed is SLC7A11; the disease is cancer.